Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class of anti-infective drugs.
The China National Intellectual Property Administration (CNIPA) formally awarded the company a ‘Patent Family 2’ for expiry in 2035.
Recce says with this final grant, it is now globally patent protected – a significant milestone for the legal side of things.
The Chinese patent covers R327 and R529, two of the anti-infective products Recce is running with as flagship products – namely, manufacturing rights.
Recce highlighted on Tuesday that China boasts the second largest pharmaceutical market in the world, worth some US$140B in 2021 according to its own calculations.
The company also reported an annual industry growth rate of 3.2% in 2023, expected to grow further based in research from Ibis World.
“We thank the China National Intellectual Property Administration for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” Recce chief James Graham said.
“We are proud to have now completed our portfolio of Family 2 Patents and now have coverage globally until at least 2035.”
RCE last traded at 66cps.